OBJECTIVES: This study is a prospective randomized trial investigating clinical outcomes of patients with acute myocardial infarction (AMI) treated withabciximab (ReoPro)-coated stents. BACKGROUND: Recently we have demonstrated that abciximab-coated stents have inhibitory effects in the prevention of coronary restenosis. METHODS:Ninety-six patients with AMI were randomly allocated into two groups; group I received abciximab-coated stents (n = 48, 57.1 +/- 12.0 years), and group II received bare metal control stents (n = 48, 58.4 +/- 11.6 years). RESULTS: At baseline, clinical characteristics, percent diameter stenosis, and minimal luminal diameter were no different between the two groups. One patient in group II had reinfarction and target lesion reintervention during hospital stay. Follow-up coronary angiography was obtained in 77.1% (37 of 48) in group I and 75.0% (36 of 48) in group II. Percent diameter stenosis and late loss were significantly lower in group I than group II (18.9 +/- 5.54% vs. 37.9 +/- 6.25%, p = 0.008; and 0.39 +/- 0.29 mm vs. 0.88 +/- 0.45 mm; p = 0.008, respectively). At follow-up intravascular ultrasound, intrastent lumen area and intrastent neointimal hyperplasia (NIH) area were 5.4 +/- 1.8 mm2 and 2.2 +/- 1.5 mm2, respectively, in group I and 4.3 +/- 1.6 mm2 and 3.4 +/- 1.8 mm2, respectively, in group II (p = 0.045). And, in-stent restenosis rate was lower in group I than group II (p = 0.011 and p = 0.008, respectively). During 1-year follow-up, two patients in group II (4.1%) had AMI, whereas no patient in group I suffered AMI. Target lesion revascularization and total major adverse cardiac events rates were relatively lower in group I compared with those in group II (10.4% [5 of 48] vs. 20.8% [10 of 48], p = 0.261, and 10.4% vs. 25.0%, p = 0.107, respectively). CONCLUSIONS:Abciximab-coated stent implantation was safe and effective without stent thrombosis in AMI patients.
RCT Entities:
OBJECTIVES: This study is a prospective randomized trial investigating clinical outcomes of patients with acute myocardial infarction (AMI) treated with abciximab (ReoPro)-coated stents. BACKGROUND: Recently we have demonstrated that abciximab-coated stents have inhibitory effects in the prevention of coronary restenosis. METHODS: Ninety-six patients with AMI were randomly allocated into two groups; group I received abciximab-coated stents (n = 48, 57.1 +/- 12.0 years), and group II received bare metal control stents (n = 48, 58.4 +/- 11.6 years). RESULTS: At baseline, clinical characteristics, percent diameter stenosis, and minimal luminal diameter were no different between the two groups. One patient in group II had reinfarction and target lesion reintervention during hospital stay. Follow-up coronary angiography was obtained in 77.1% (37 of 48) in group I and 75.0% (36 of 48) in group II. Percent diameter stenosis and late loss were significantly lower in group I than group II (18.9 +/- 5.54% vs. 37.9 +/- 6.25%, p = 0.008; and 0.39 +/- 0.29 mm vs. 0.88 +/- 0.45 mm; p = 0.008, respectively). At follow-up intravascular ultrasound, intrastent lumen area and intrastent neointimal hyperplasia (NIH) area were 5.4 +/- 1.8 mm2 and 2.2 +/- 1.5 mm2, respectively, in group I and 4.3 +/- 1.6 mm2 and 3.4 +/- 1.8 mm2, respectively, in group II (p = 0.045). And, in-stent restenosis rate was lower in group I than group II (p = 0.011 and p = 0.008, respectively). During 1-year follow-up, two patients in group II (4.1%) had AMI, whereas no patient in group I suffered AMI. Target lesion revascularization and total major adverse cardiac events rates were relatively lower in group I compared with those in group II (10.4% [5 of 48] vs. 20.8% [10 of 48], p = 0.261, and 10.4% vs. 25.0%, p = 0.107, respectively). CONCLUSIONS:Abciximab-coated stent implantation was safe and effective without stent thrombosis in AMI patients.
Authors: Jung Sun Cho; Myung Ho Jeong; Doo Sun Sim; Young Joon Hong; Kyung Seob Lim; Jung Ha Kim; Hyoung Doo Kim; Ju Yeal Baek; Hee Jeoung Yoon; Sung-Ho Her; Seung Won Jin; Ju Han Kim; Youngkeun Ahn; Jeong Gwan Cho; Jong Chun Park; Jung Chaee Kang Journal: J Korean Med Sci Date: 2010-04-16 Impact factor: 2.153
Authors: Keun-Ho Park; Myung Ho Jeong; Min Goo Lee; Jum Suk Ko; Shin Eun Lee; Won Yu Kang; Soo Hyun Kim; Doo Sun Sim; Nam Sik Yoon; Hyun Ju Youn; Young Joon Hong; Hyung Wook Park; Ju Han Kim; Youngkeun Ahn; Jeong Gwan Cho; Jong Chun Park; Jung Chaee Kang Journal: Korean Circ J Date: 2009-05-28 Impact factor: 3.243
Authors: Kyung Seob Lim; In Ho Bae; Jung Ha Kim; Dae Sung Park; Jong Min Kim; Jung Hyun Kim; Doo Sun Sim; Young Joon Hong; Myung Ho Jeong Journal: Chonnam Med J Date: 2013-04-25
Authors: Young Joon Hong; Myung Ho Jeong; Sang Rok Lee; Seo Na Hong; Kye Hun Kim; Hyung Wook Park; Ju Han Kim; Weon Kim; Youngkeun Ahn; Jeong Gwan Cho; Jong Chun Park; Jung Chaee Kang Journal: J Korean Med Sci Date: 2007-10 Impact factor: 2.153